STOCK TITAN

Kiniksa Pharmaceuticals Ltd - KNSA STOCK NEWS

Welcome to our dedicated news page for Kiniksa Pharmaceuticals (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kiniksa Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kiniksa Pharmaceuticals's position in the market.

Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. reported strong financial results for Q4 2023 and full-year 2023 with net product revenue of $71.2 million and $233.2 million, respectively. They expect ARCALYST 2024 revenue to reach $360 - $380 million, representing a 59% YoY growth. The company's cash reserves of $206.4 million are expected to fund operations until at least 2027. Positive Phase 2 data for abiprubart in rheumatoid arthritis and plans for a new indication in April 2024 were highlighted. Kiniksa also recognized positive clinical trial results for mavrilimumab and a development milestone for vixarelimab. Financially, total revenue increased to $270.3 million in 2023, with net income of $14.1 million for the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
earnings
-
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on February 28, 2024, to report its Q4 and full-year 2023 financial results and recent portfolio execution. Interested individuals can access the webcast through the company's website or participate via telephone by registering. A replay will be available on Kiniksa's website post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences earnings
-
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported a 90% year-over-year growth in ARCALYST net product revenue to $233.1 million in 2023. They expect ARCALYST 2024 net product revenue to be between $360 - $380 million. Abiprubart (KPL-404) Phase 2 rheumatoid arthritis trial met the primary efficacy endpoint in Cohort 3 at the weekly dose level. Cash reserves of $206.3 million are expected to fund operations into at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
none
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
conferences
-
Rhea-AI Summary
Kiniksa Pharmaceuticals reports Q3 2023 net product revenue of $64.8 million, a 94% YoY growth. KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024. Cash reserves of $201 million expected to fund operations into at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
earnings
-
Rhea-AI Summary
Kiniksa Pharmaceuticals to report Q3 2023 financial results and recent portfolio execution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences earnings
Rhea-AI Summary
Kiniksa Pharmaceuticals reports Q2 2023 net product revenue of $54.5 million, increases 2023 net product revenue guidance to $220-$230 million, expects Phase 2 rheumatoid arthritis data in 1H 2024, and extends cash reserves to at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.39%
Tags
earnings
-
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution. The webcast will be accessible through the company's website. Telephone participants can register to receive a confirmation email with details on how to join the call. A replay of the event will be available on Kiniksa's website within approximately 48 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.02%
Tags
conferences earnings
-
Rhea-AI Summary
Kiniksa Pharmaceuticals to participate in fireside chat at Goldman Sachs healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.66%
Tags
earnings
Kiniksa Pharmaceuticals Ltd

Nasdaq:KNSA

KNSA Rankings

KNSA Stock Data

1.41B
31.63M
3.94%
89.51%
3.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Bermuda
Hamilton

About KNSA

kiniksa pharmaceuticals combines an experienced management team and significant committed capital in order to acquire, develop, and commercialize therapeutics treating devastating diseases with high unmet needs.